Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Vamorolone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 26,041Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Santhera Secures Swissmedic Approval for AGAMREE in DMD
    Santhera Secures Swissmedic Approval for AGAMREE in DMD

    15 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/15/3219228/0/en/Santhera-Receives-Swissmedic-Approval-of-AGAMREE-Vamorolone-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html

    GLOBENEWSWIRE
    15 Jan 2026
    Share Share
    Nxera Pharma Licenses Vamorolone For Duchenne Muscular Dystrophy
    Nxera Pharma Licenses Vamorolone For Duchenne Muscular Dystrophy

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215065/0/en/Nxera-Pharma-Licenses-Japan-and-Select-Asia-Pacific-Rights-to-Vamorolone-for-Duchenne-Muscular-Dystrophy-from-Santhera-Pharmaceuticals.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    Santhera Closes USD 13 Million Royalty Monetization Agreement
    Santhera Closes USD 13 Million Royalty Monetization Agreement

    05 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-05/santhera-closes-usd-13-million-royalty-monetization-agreement

    PHARMIWEB
    05 Nov 2025
    Share Share
    AGAMREE (Vamorolone) Shows Safer Profile In DMD Patients
    AGAMREE (Vamorolone) Shows Safer Profile In DMD Patients

    04 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-04/five-year-data-of-agamree-vamorolone-in-patients-with-dmd-show-improved-safety-profile-with-comparable-effectiveness-to-standard-of-care-corticoste

    PHARMIWEB
    04 Nov 2025
    Share Share
    Santhera Partners Biomedica For AGAMREE® Distribution In Russia
    Santhera Partners Biomedica For AGAMREE® Distribution In Russia

    09 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/09/3163838/0/en/Santhera-Secures-Agreement-with-Biomedica-for-the-Distribution-of-AGAMREE-Vamorolone-in-Russia.html

    GLOBENEWSWIRE
    09 Oct 2025
    Share Share
    Santhera Gets Canada Approval For AGAMREE® In DMD
    Santhera Gets Canada Approval For AGAMREE® In DMD

    03 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/03/3160773/0/en/Santhera-Announces-Approval-in-Canada-for-AGAMREE-Vamorolone-as-a-Treatment-for-Duchenne-Muscular-Dystrophy.html

    GLOBENEWSWIRE
    03 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.